CrunchBase is hiring! Check out our open positions →
Register | Login or Login

General Information

Websitegenocea.com
CategoryBioTech
Phone617.876.8191
Emailwebsite.inquiry@g...
Employees
Founded2006

Offices

Cambridge, USA
161 First St.
Suite 2C
Cambridge, MA, 02142
USA

People

Funding

Tags

Genocea Biosciences

Genocea is developing a new class of human vaccines based on a revolutionary platform for the rapid discovery of antigens that induce T cell immunity. The platform, which dramatically reduces the time to discover vaccine candidates, uniquely employs a proprietary, high-throughput approach that mimics the natural immune response in the laboratory to comprehensively screen for antigens that are protective across diverse human populations. Genocea has demonstrated preclinical proof-of-concept with vaccines for herpes simplex virus type 2 (HSV-2), Streptococcus pneumoniae, and Chlamydia trachomatis, infections that affect hundreds of millions of people worldwide. The company expects to begin clinical trials for its lead program, a therapeutic vaccine for HSV-2, in early 2011.

Recent Milestones

Videos

Screenshots

Sources

  1. Genocea Biosciences Closes $35M Series B Financing Round (finsmes.com) [edit]
  2. Genocea raises $30M to advance herpes vaccine (masshightech.com) [edit]
  3. Genocea's $35M VC round pushing herpes vaccine toward clinic (masshightech.com) [edit]
    Clark named CEO at Genocea Biosciences (masshightech.com) [edit]
Edit This Page
Last Edited 4/16/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy